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http://dx.doi.org/10.1016/j.pedneo.2
1875-9572/Copyrightª 2016, Taiwan P
NC-ND license (http://creativecommoBackground: The present study was conducted to assess the maternal and cord blood hepcidin
concentrations in severe iron deficiency anemia (IDA) and to find out its correlation with other
iron status parameters.
Methods: This prospective observational study was carried out in 30 mothers with severe IDA
(hemoglobin < 70 g/L and serum ferritin < 12 mg/L), and 15 healthy nonanemic (hemoglobin
 110 g/L) mothers, who delivered live singleton neonates at term gestation. Mothers and ne-
onates with infection/inflammatory conditions were excluded. Quantitative estimation of
complete blood count, serum iron, ferritin, total iron binding capacity (TIBC), and transferrin
saturation (Tfsat) was done in maternal and cord blood immediately after delivery by an auto
analyzer. Serum hepcidin concentrations were measured by double-antibody sandwich
enzyme-linked immunosorbent assay using a Human Hepcidin-25 kit. Data were analyzed by
statistical software SPSS 16.0.
Results: The serum iron and ferritin concentrations in severe IDA were 6.7  1.8 mmol/L and
4.1  1.4 mg/L in maternal blood, and 9.5  2.6 mmol/L and 55.4  19.7 mg/L in cord blood,
respectively, significantly lower than nonanemic controls (p < 0.001). The corresponding
serum hepcidin concentrations were 76.6  22.7 mg/L and 110.5  11.8 mg/L, respectively
(p < 0.05). The proportion of cord blood/maternal blood hepcidin concentration was similar
in both anemic (1.4:1) and nonanemic (1.3:1) mothers. Significant correlation was observed
among maternal and cord blood hepcidin concentrations and other iron status parameters.
Conclusion: Even in the presence of low serum iron and ferritin, maternal and cord bloodparna Basu, Neonatology Unit, Department of Pediatrics, Institute of Medical Sciences, Banaras Hindu
diffmail.com (S. Basu).
015.09.012
ediatric Association. Published by Elsevier Taiwan LLC. This is an open access article under the CC BY-
ns.org/licenses/by-nc-nd/4.0/).
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sion of hepcidin indicates poor systemic bioavailability of iron to the mother and poor
placental transport.
Copyright ª 2016, Taiwan Pediatric Association. Published by Elsevier Taiwan LLC. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).1. Introduction
Iron is an essential micronutrient, necessary for oxygen
transport and other vital biological processes of life.
Worldwide, iron deficiency anemia (IDA) is the most com-
mon nutritional deficiency1 and one of the major causes of
anemia during pregnancy. As per the recent estimates, the
worldwide prevalence of anemia in pregnant women is
approximately 38%, and in > 50% of them, the cause of
anemia is iron deficiency.2 The rate is even higher in
developing countries, and India has the highest prevalence
of maternal anemia in the world.3
Iron is necessary to support placental and fetal growth.
Maternal IDA not only increases the incidence of maternal
morbidity and mortality, but it also increases the risk of
premature delivery, fetal growth restriction, and perinatal
mortality and morbidity.4e6 Moreover, maternal IDA pre-
cludes healthy neurodevelopment of the fetus, since iron is
essential for proper neurogenesis, myelination, and neu-
rocognitive maturity.7,8 Impaired fetal iron transport may
have lifelong, irreversible effects on future
neurodevelopment.9
Iron requirement increases by nearly 10 times during
pregnancy (0.8 mg/d in the 1st trimester to 7.5 mg/d in the
3rd trimester),10 making iron accessibility critical
throughout pregnancy. The developing fetus is entirely
dependent on its mother for iron accretion, which takes
place almost exclusively via the placenta. Placental iron
homeostasis results from the tightly coordinated regulation
of various proteins involved in iron uptake, transport,
intracellular storage, and iron trafficking. The major regu-
lator of systemic iron bioavailability in the human body is
hepcidin, a small 25 amino acid amphipathic peptide hor-
mone.11 Hepcidin has also been documented recently to be
one of the key determinants of placental transport of iron
and the regulator of maternofetal iron transfer during
pregnancy.12 The fetal hepcidin-placental-ferroportin axis
represents an important element in the fetus-dependent
control of iron transport through the placenta.13
In a developing country like India, most pregnant women
are iron-depleted and hardly receive any nutritional or iron
supplementation during pregnancy. Although previous au-
thors have shown a significant association among placental
transport of iron and maternal hepcidin concen-
tration,11,12,14e17 no study has documented the state of
maternal and fetal hepcidin concentration in the presence of
severe maternal IDA. In the present study, we measured
serum hepcidin and other iron status parameters, such as
complete blood count, serum iron, ferritin, total iron binding
capacity (TIBC), and transferrin saturation (Tfsat) inmotherswith severe IDA and cord blood of their neonates. We also
looked for any correlations among the parameters.2. Methods
This study was carried out in the Neonatal Unit, Depart-
ment of Pediatrics, Institute of Medical Sciences, Banaras
Hindu University, Varanasi, India, after obtaining approval
from the Institute Ethics Committee.2.1. Study participants
Consecutively admitted mothers with severe IDA, who
delivered live singleton neonates at term gestation
(37e41 weeks), formed the case group. Severe IDA was
defined as a hemoglobin < 70 g/L and serum ferritin <
12 mg/L. Mothers with hemolytic anemias including thalas-
semia and sickle cell anemia, chronic infection/inflamma-
tory diseases, hemochromatosis, chronic kidney disease,
chorioamnionitis, infection with human immunodeficiency
virus/ hepatitis B/syphilis, Toxoplasma, Rubella, Cytomeg-
alovirus, Herpes (TORCH) infections, malaria, pregnancy
induced hypertension, diabetes, and other obstetric com-
plications were excluded from the study. Neonates with
perinatal asphyxia, early-onset neonatal sepsis, isoimmune
hemolytic anemias, and congenital malformations were
also excluded.
Healthy nonanemic mothers with hemoglobin  110 g/L,
delivering live singleton neonates at term gestation, served
as controls. A written informed consent in the local lan-
guage was taken from all parents before inclusion in the
study.2.2. Clinical work-up
Demographic details, as well as antenatal and perinatal
history including iron and folic acid supplementation
received by the mother during pregnancy, were noted.
Nutritional status of the mother was determined by
measuring weight, height, and body mass index after at
least 48 hours of childbirth. Neonates were examined
thoroughly after birth to exclude any congenital malfor-
mation or other systemic diseases. Birth weight was taken
soon after birth. Gestational age was assessed from
maternal history and antenatal ultrasound, and clinically
corroborated after birth by the New Ballard Score.18 Neo-
nates were observed for development of any complications
during the hospital stay and managed as per our unit
protocol.
Serum hepcidin in maternal anemia 4152.3. Collection of samples and laboratory analysis
After complete delivery of the neonate, 5 mL of maternal
venous blood was collected by aseptic venipuncture of a
peripheral vein. Free flowing cord blood (10 mL) was
collected from the placental end of the umbilical cord
without milking. Quantitative estimation of complete blood
count was done by an auto analyzer (Coulter LH 750 He-
matology Analyzer, Beckman Coulter, Inc., Brea, CA, USA).
For the measurement of serum iron, ferritin, TIBC, and
Tfsat, serum was separated immediately by centrifugation
(448e700 g/min for 15e20 minutes) and was measured by
an auto analyzer (RX Suzuka Clinical Chemistry Analyzer,
Randox, Inc., Crumlin, UK). For the estimation of hepcidin,
serum was stored at 20C until final analysis and measured
by double-antibody sandwich enzyme-linked immunosor-
bent assay using a Human Hepcidin-25 (HEPC25) (Hangzhou
Eastbiopharm Co. Ltd. Hangzhou, Zhejiang, China) kit.2.4. Statistical analysis
The statistical program SPSS version 16.0 (SPSS Inc., Chi-
cago, IL, USA) was used for data entry and analysis. The
Mann Whitney U test and Fisher’s exact test were used to
compare different variables. Spearman correlation was
calculated to identify correlation among various parame-
ters. A p value < 0.05 was considered as statistically
significant.Table 1 Baseline characteristics of the study population.
Parameter Nonanemic mothers
(maternal Hb  110 g/L)
(n Z 15)
Maternal characteristics
Age (y) 26.3  3.4
Body mass index (kg/m2) 24.3  3.9
Gravida 1 (1e3)
Parity 0 (0e1)
Antenatal care taken 12 (80.0)
Vegetarian dietary habit 7 (46.7)
Iron & folate supplementation 15 (100.0)
Details of delivery
Mode of delivery
SVD 12 (80.0)
Cesarean section 3 (20.0)
Presentation
Vertex 15 (100.0)
Breech 0 (0.0)
Neonatal characteristics
Gestational age (wk) 38.8  1.5
39
(38e40)
Birth weight (g) 3002  428
3000 (2600e3250)
Apgar score 9 (7e10)
Data are presented as n (%), mean  standard deviation, or median (
Hb Z hemoglobin; SVD Z spontaneous vaginal delivery.3. Results
A convenient sample of 30 mothers with severe IDA and
their neonates were included as cases. Fifteen healthy
mothers without anemia along with their infants served as
controls. The baseline characteristics of the study popula-
tion are shown in Table 1. Among maternal parameters,
body mass index, receipt of antenatal care, dietary habits,
and status of iron and folic acid supplementation were
significantly better in nonanemic mothers. Among neonatal
parameters, mean birth weight of the neonates born to
nonanemic mothers was significantly higher than the
anemic mothers (3002  428 g vs. 2396  305 g; p < 0.001),
although no difference was observed in mean gestational
age. None of the mothers in any group was obese.
The mean hemoglobin, serum iron, and serum ferritin of
anemic mothers were significantly lower than the non-
anemic mothers both in maternal and the cord blood
(p < 0.001). Serum hepcidin concentrations of anemic
mothers were also lower in the maternal and the cord
blood, but the difference was only modest (76.6  22.7 mg/
L vs. 92.4  10.5 mg/L in maternal blood and
110.5  11.8 mg/L vs. 124.0  17.4 mg/L in cord blood,
respectively; p < 0.05; Table 2).
Table 3 shows the relationship between maternal and
cord blood iron status parameters and serum hepcidin. Both
in anemic and nonanemic mothers, most of the iron pa-
rameters were significantly higher in the cord blood.
Maximum difference was observed for serum ferritin and
the differences were lower for serum iron and hepcidin.Anemic mothers
(maternal Hb < 70 g/L)
(n Z 30)
Mann Whitney U testa/Fisher’s
exact testb
25.3  3.7 0.385 (NS)a
20.8  3.2 < 0.01a
1 (1e3) 1.000 (NS)a
0 (0e1) 0.146 (NS)a
4 (13.3) < 0.001b
24 (80.0) < 0.03b
2 (6.7) < 0.001b
24 (80.0) 1.000 (NS)b
6 (20.0)
28 (93.3) 0.545 (NS)b
2 (6.7)
38.9  1.3
39 0.940 (NS)a
(38e40)
2396  305 < 0.001a
2460 (2188e2605)
8 (7e9) 1.000 (NS)a
interquartile range).
Table 2 Comparison of the maternal and cord blood hemoglobin, iron indices, and hepcidin concentration of the study
population.
Parameter Nonanemic mothers
(maternal Hb  110 g/L)
(n Z 15)
Anemic mothers
(maternal Hb < 70 g/L)
(n Z 30)
Mann Whitney U test Controls/cases ratio
Maternal blood
Hemoglobin (g/L) 129  8 55  14 < 0.001 2.3:1
Serum iron (mmol/L) 22.9  5.8 6.7  1.8 < 0.001 3.4:1
Serum ferritin (mg/L) 21.2  3.6 4.1  1.4 < 0.001 5.2:1
TIBC (mmol/L) 40.5  11.5 95.4  14.0 < 0.001 0.4:1
Transferrin saturation (%) 48.2  15.7 7.3  2.4 < 0.001 6.6:1
Serum hepcidin (mg/L) 92.4  10.5 76.6  22.7 < 0.05 1.2:1
Median 92.4 84.9
Percentiles
5 67.5 33.6
95 108.3 107.5
Cord blood
Hemoglobin (g/L) 163  16 122  10 < 0.001 1.3:1
Serum iron (mmol/L) 23.8  3.2 9.5  2.6 < 0.001 2.5:1
Serum ferritin (mg/L) 159.7  26.3 55.4  19.7 < 0.001 2.9:1
TIBC (mmol/L) 48.8  6.9 77.6  11.2 < 0.001 0.6:1
Transferrin saturation (%) 48.2  15.7 12.5  4.2 < 0.001 3.8:1
Serum hepcidin (mg/L) 124.0  17.4 110.5  11.8 < 0.05 1.12:1
Median 117.2 109.3
Percentiles
5 97.6 94.8
95 151.2 135.6
Data are presented as mean  standard deviation, unless otherwise indicated.
TIBC Z total iron binding capacity.
Table 3 The relationship between maternal and cord blood iron status parameters and serum hepcidin in nonanemic and
anemic mothers.
Parameter Cord blood Maternal blood Mann Whitney U test Cord blood/maternal
blood ratio
Nonanemic mothers
(maternal Hb  110 g/L)
(n Z 15)
Hemoglobin (g/L) 163  16 129  8 < 0.001 1.3:1
Serum iron (mmol/L) 23.8  3.2 22.9  5.8 0.570 (NS) 1.03:1
Serum ferritin (mg/L) 159.7  26.3 21.2  3.6 < 0.001 7.5:1
TIBC (mmol/L) 48.8  6.9 40.5  11.5 < 0.05 1.2:1
Transferrin saturation (%) 61.8  14.0 48.2  15.7 < 0.05 1.3:1
Serum hepcidin (mg/L) 124.0  17.4 110.5  11.8 < 0.001 1.3:1
Anemic mothers
(Maternal Hb < 70 g/L)
(n Z 30)
Hemoglobin (g/L) 122  10 55  14 < 0.001 2.2:1
Serum iron (mmol/L) 9.5  2.6 6.7  1.8 < 0.01 1.4:1
Serum ferritin (mg/L) 55.4  19.7 4.1  1.4 < 0.001 13.5:1
TIBC (mmol/L) 77.6  11.2 95.4  14.0 < 0.001 0.8:1
Transferrin saturation (%) 12.5  4.2 7.3  2.4 < 0.01 1.7:1
Serum hepcidin (mg/L) 110.5  11.8 76.6  22.7 < 0.001 1.4:1
Data are presented as mean  standard deviation.
TIBC Z total iron binding capacity.
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Table 4 Spearman correlation among maternal and cord blood hemoglobin, iron indices, and hepcidin.
Maternal
iron
Maternal
ferritin
Maternal
TIBC
Maternal
Tfsat
Maternal
hepcidin
Cord
blood Hb
Cord blood
iron
Cord blood
ferritin
Cord
blood TIBC
Cord
blood Tfsat
Cord blood
l hepcidin
Maternal
Hb
Correlation 0.941* 0.942* 0.894* 0.903* 0.486* 0.827* 0.884* 0.917* 0.778* 0.870* 0.556*
Sig. (2-tailed) < 0.001 < 0.001 < 0.001 < 0.001 0.001 < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 < 0.001
Maternal iron Correlation 1 0.945* 0.886* 0.961* 0.361y 0.807* 0.873* 0.907* 0.791* 0.866* 0.401*
Sig. (2-tailed) _ < 0.001 < 0.001 < 0.001 0.015 < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 0.006
Maternal
ferritin
Correlation _ 1 0.873* 0.926* 0.373y 0.888* 0.907* 0.939* 0.814* 0.926* 0.439*
Sig. (2-tailed) _ _ < 0.001 < 0.001 0.012 < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 0.003
Maternal TIBC Correlation _ _ 1 0.923* 0.417* 0.838* 0.750* 0.842* 0.803* 0.786* 0.404*
Sig. (2-tailed) _ _ _ < 0.001 0.004 < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 0.006
Maternal Tfsat Correlation _ _ _ 1 0.330y 0.844* 0.811* 0.896* 0.800* 0.841* 0.346y
Sig. (2-tailed) _ _ _ _ 0.027 < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 0.020
Maternal hepcidin Correlation _ _ _ _ 1 0.386* 0.365y 0.368y 0.237 0.329y 0.717*
Sig. (2-tailed) _ _ _ _ _ 0.009 0.014 0.013 0.117 0.027 < 0.001
Cord blood Hb Correlation _ _ _ _ _ 1 0.798* 0.866* 0.779* 0.846* 0.388*
Sig. (2-tailed) _ _ _ _ _ _ < 0.001 < 0.001 < 0.001 < 0.001 0.008
Cord blood iron Correlation _ _ _ _ _ _ 1 0.868* 0.738* 0.965* 0.443*
Sig. (2-tailed) _ _ _ _ _ _ _ < 0.001 < 0.001 < 0.001 0.002
Cord blood l ferritin Correlation _ _ _ _ _ _ _ 1 0.787* 0.882* 0.457*
Sig. (2-tailed) _ _ _ _ _ _ _ _ < 0.001 < 0.001 0.002
Cord blood TIBC Correlation _ _ _ _ _ _ _ _ 1 0.828* 0.291
Sig. (2-tailed) _ _ _ _ _ _ _ _ _ < 0.001 0.052
Cord blood Tfsat Correlation _ _ _ _ _ _ _ _ _ 1 0.358y
Sig. (2-tailed) _ _ _ _ _ _ _ _ _ _ 0.016
Hb Z hemoglobin; TIBC Z total iron binding capacity; Tfsat Z transferrin saturation.
* Correlation is significant at the 0.01 level (2-tailed).
y Correlation is significant at the 0.05 level (2-tailed).
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concentration was similar in both anemic (1.4:1) and non-
anemic (1.3:1) mothers.
Spearman correlation among different parameters is
shown in Table 4. Significant correlations were observed
among all the iron status parameters. Maternal hepcidin
was significantly correlated with cord blood hepcidin con-
centration and other iron status parameters.4. Discussion
Hepcidin is the major regulatory hormone for iron homeo-
stasis. It inhibits iron absorption or reutilization by binding
to ferroportin, the major iron exporter, leading to its
internalization and degradation, and thereby decreasing
the export of iron into plasma. The most important down-
regulator of serum hepcidin is anemia and poor iron
status.19
The normal serum hepcidin concentration in healthy
women volunteers ranges from 17 ng/mL or mg/L to 286 ng/
mL or mg/L (5e95%).20 Serum hepcidin concentrations were
reported to decrease with the advancement of pregnancy.
Several longitudinal studies observed the lowest hepcidin
concentrations in the third trimester.16,21e23 Increasing
need for fetal iron and decreasing maternal iron levels in
the third trimester were the probable reasons for the
decrease in maternal hepcidin in the third trimester.24
Hepcidin concentration in pregnant women with lowest
iron status was found to be the lowest.15 In the present
study, the serum iron and ferritin concentrations in severe
IDA were as low as 6.7  1.8 mmol/L and 4.1  1.4 mg/L in
maternal blood and 9.5  2.6 mmol/L and 55.4  19.7 mg/L
in cord blood, respectively. The corresponding serum hep-
cidin concentrations were 76.6  22.7 mg/L and
110.5  11.8 mg/L, respectively.
Ganz et al20 observed that mean hepcidin concentration
in normal term infants was 90.7 ng/mL, similar to that in
adults. The observed values of serum hepcidin in studies
done in anemic mothers ranged from undetectable15 to
quite low, geometric mean (95% confidence intervals) 2.8
(0.5e13.1) nmol/L25 to 10.7 (8.5e13.4) ng/mL.15 In our
study, the cord blood hepcidin concentrations were only 1.4
times higher than the maternal levels in severe IDA and the
ratio was similar to the mothers without anemia (1.3:1). In
the study of Rehu et al15 the cord blood values were almost
six times higher than those in maternal blood. In our study,
serum hepcidin concentrations in nonanemic mothers were
92.4  10.5 mg/L. Most studies done in developed countries
reported undetectable to very low median values for
maternal serum hepcidin concentrations, such as unde-
tectable to 0.25 nmol/L,16 9.5 ng/mL in the third
trimester,22 3.0 nmol/L at 24 hours postpartum,16 from
2.52 ng/mL to 2.83 ng/mL,21 and 4.2 (1.6e8.0) nmol/L,25
whereas one Asian study reported very high maternal
serum hepcidin concentrations of 193.637  52.219 mg/L.26
No study has been done so far from India. Contrary to other
studies,15,27 we have found significant correlation among
maternal and cord blood hepcidin concentrations and other
iron status parameters.
Although the iron requirement of the fetus is met
regardless of maternal iron stores, iron trafficking in fetalorgans and tissues through the placenta is tightly regu-
lated, as the developing fetus is extremely vulnerable to
iron toxicity and free radical-mediated oxidative stress.28
Studies have shown that ferroportin is present in the basal
membrane of the syncytiotrophoblasts exporting iron from
the syncytiotrophoblasts into the fetal circulation.29 It is
not yet known exactly how iron crosses the barrier of the
fetal vascular endothelium and enters the fetal circula-
tion from the syncytiotrophoblasts, because ferroportin is
not expressed on fetal blood vessels.29 Hepcidin is pivotal
for fetal iron homeostasis. It mediates the regulation of
iron efflux from the placenta by controlling the rate of
iron absorption and also determining iron mobilization
from stores through negative modulation of the function
of ferroportin at the basolateral membrane of syncytio-
trophoblasts, inhibiting iron release from placental
cells.13 Immunohistochemical demonstration of hepcidin
molecules in the villous syncytiotrophoblast and the
mesothelial layer of the secondary yolk sac by Evans
et al30 supported this view. Moreover, animal experiments
have shown that transferrin receptor 1, expressed on the
apical membrane of the syncytiotrophoblasts, another
major iron transporter of placenta,31 is also regulated by
hepcidin.32
In the present study, mean birth weight of neonates born
to mothers with severe IDA was significantly lower. Low
birth weight and intrauterine growth restriction (IUGR) are
common complications of maternal IDA.4,5 Briana et al27
investigated iron homeostasis in full-term IUGR and
appropriate-for-gestational-age infants at birth. The au-
thors did not find any difference in hepcidin concentrations
between the groups.
In the presence of low serum iron and ferritin, serum
hepcidin concentrations should have been reduced further
in severe IDA. The mothers were already compromised by
their limited access to both heme and non-heme sources of
iron, since most of them were vegetarian and did not
receive any iron supplementation during pregnancy. Failure
of proportional suppression of serum hepcidin further
compromised their iron absorption and reutilization,
resulting in poor placental transfer and reduced systemic
bioavailability of iron to the fetus. The exact reason of high
hepcidin concentration is difficult to explain. We tried to
exclude the factors which could increase maternal and cord
blood hepcidin concentrations, such as infection and in-
flammatory states, preeclampsia etc.24 Downregulation of
genes responsible for hepcidin expression in mothers with
long-standing anemia could be the responsible factor, but
this is only a speculation.
Our study was limited by its sample size. Inclusion of
mothers with mild-to-moderate anemia in the study group
would have been interesting to observe the status of hep-
cidin in those cases. Secondly, we measured serum hepcidin
only after delivery; following up the mothers from the
beginning of pregnancy to childbirth would have yielded
important information. Moreover, we did not examine the
placenta. Immunohistochemistry staining of placenta for
hepcidin receptors would have been informative, but it was
beyond our study protocol.
To conclude, failure of suppression of maternal and cord
blood hepcidin concentrations, even in the presence of
poor iron status, is alarming for the mother as well for her
Serum hepcidin in maternal anemia 419developing fetus, as it may have long-term consequences.
Optimization of the nutritional intake during pregnancy
should be ensured. Future longitudinal studies may be
carried out to identify the contributing factors for timely
implementation of necessary corrective measures.
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